Press Releases

August 16, 2024
BITT Announced CD40 Otsuka Research and Exclusivity Agreement and New NIH Funding for TNFR2 Clinical Trial
Business Wire

August 31, 2023
BITT Announces NIH Award for Advancement of Anti-CD40 Antibody
Business Wire

August 18, 2023
BITT Announces FDA Acceptance of IND for TNFR2 Antibody
Business Wire

May 2, 2023
BITT To Present Update on CD40 Program at AAI 2023
Business Wire

December 14, 2021
BITT Announces NIH SBIR Award and New Board Member
BITT

March 17, 2021
Boston Immune Technologies and Therapeutics Raises $10M Series A Financing
Business Wire

March 9, 2021
Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lead TNFR2 Oncology Candidate
Business Wire

February 17, 2021
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
Business Wire

January 31, 2021
Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
globenewswire.com

In The News

Beigene strikes its second overseas deal this year with BITT for TNFR2 antibodies
BioWorld | 2021-02-23

A month after multi-billion dollar Novartis deal, BeiGene follows up with ‘reverse’ deal
Endpoints News

BeiGene In-Licenses TNF-based Immunotherapy in $126 Million Agreement
Chinabiotoday.com

BioCentury Emerging Company Profile (PDF)
BioCentury | March 2018

Publications on TNF Superfamily Antagonism

June 2022
The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy | Cells

January 13, 2022
Signal Amplification in Highly Ordered Networks Is Driven by Geometry | Cells

November 2021
A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer | International Immunopharmacology

March 2, 2021
Structures of mouse and human GITR–GITRL complexes reveal unique TNF superfamily interactions | Nature Communications

February 22, 2021
A TNFR2-hnRNPK axis promotes primary liver cancer development via activation of YAP signaling in hepatic progenitor cells | Cancer Research (aacrjournals.org)

December 2020
Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis – PubMed (nih.gov)

June 2020
Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity – PubMed (nih.gov)

May 24, 2020
TNFR2 blockade alone or in combination with PD‐1 blockade shows therapeutic efficacy in murine cancer models – Case – 2020 – Journal of Leukocyte Biology – Wiley Online Library

May 2020
Targeting TNFR2 to overcome acquired adaptive resistance to immune checkpoint blockade | The Journal of Immunology (jimmunol.org)

March 24, 2020
Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL – PubMed (nih.gov)

August 5, 2019
CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches – PubMed (nih.gov)

May 2019
Targeted killing of TNFR2-expressing tumor cells and T regs by TNFR2 antagonistic antibodies in advanced Sézary syndrome – PubMed (nih.gov)

May 28, 2018
Frontiers | TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors | Immunology (frontiersin.org)

January 2, 2018
Structural principles of tumor necrosis factor superfamily signaling | Science Signaling (sciencemag.org)

January 2, 2018
Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer | Science Signaling (sciencemag.org)

January 2017
Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs – PubMed (nih.gov)